XML 66 R25.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Taxes on Income | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Taxes on Income | Taxes on Income A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:
| 2024 |  | 2023 |  | 2022
| Amount |  | Tax Rate |  | Amount |  | Tax Rate |  | Amount |  | Tax Rate
U.S. statutory rate applied to income before taxes | $ | 4,186 |  |  | 21.0 | % |  | $ | 397 |  |  | 21.0 | % |  | $ | 3,453 |  |  | 21.0 | %
Differential arising from: |  |  |  |  |  |  |  |  |  |  |
Foreign earnings | (1,301) |  |  | (6.5) |  |  | (941) |  |  | (49.8) |  |  | (1,821) |  |  | (11.1) |
Tax settlements and statute lapses | (557) |  |  | (2.8) |  |  | — |  |  | — |  |  | (10) |  |  | (0.1) |
R&D tax credit | (202) |  |  | (1.0) |  |  | (214) |  |  | (11.3) |  |  | (117) |  |  | (0.7) |
Inventory donations | (71) |  |  | (0.4) |  |  | (65) |  |  | (3.5) |  |  | (52) |  |  | (0.3) |
State taxes | (39) |  |  | (0.2) |  |  | (117) |  |  | (6.2) |  |  | (110) |  |  | (0.7) |
Charges for certain research and development asset acquisitions | 554 |  |  | 2.8 |  |  | 253 |  |  | 13.4 |  |  | — |  |  | — |
Valuation allowances | 54 |  |  | 0.3 |  |  | 70 |  |  | 3.7 |  |  | 108 |  |  | 0.7 |
Restructuring | 52 |  |  | 0.3 |  |  | 41 |  |  | 2.2 |  |  | 11 |  |  | 0.1 |
GILTI and the foreign-derived intangible income deduction | 29 |  |  | 0.1 |  |  | (80) |  |  | (4.3) |  |  | 462 |  |  | 2.8 |
Acquisition-related costs, including amortization | 18 |  |  | 0.1 |  |  | 42 |  |  | 2.2 |  |  | (3) |  |  | — |
Acquisition of Prometheus | — |  |  | — |  |  | 2,139 |  |  | 113.3 |  |  | — |  |  | — |
Other | 80 |  |  | 0.4 |  |  | (13) |  |  | (0.7) |  |  | (3) |  |  | — |
| $ | 2,803 |  |  | 14.1 | % |  | $ | 1,512 |  |  | 80.0 | % |  | $ | 1,918 |  |  | 11.7 | %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the expected utilization of foreign tax credits, was a net liability of $518 million at December 31, 2024, which is comprised of a $1.2 billion tax liability included in Income taxes payable, offset by $702 million of foreign tax credits included in Other Assets that Merck expects to be applied upon the completion of the IRS’s examination of the Company’s tax returns for the 2017 and 2018 federal tax years. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the net deferred tax liability with respect to this basis difference is not practicable. The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different effective tax rates than the U.S., particularly Ireland, the Netherlands and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. The Company’s income that is subject to tax incentive grants and the Cantonal tax holiday in Switzerland is subject to the global minimum tax provision of the Organization for Economic Cooperation and Development (OECD) Pillar 2, effective in 2024. Income before taxes consisted of:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Domestic | $ | (1,849) |  |  | $ | (15,622) |  |  | $ | 1,011 |
Foreign | 21,785 |  |  | 17,511 |  |  | 15,433 |
| $ | 19,936 |  |  | $ | 1,889 |  |  | $ | 16,444 |
Taxes on income consisted of:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Current provision |  |  |  |  |
Federal | $ | 944 |  |  | $ | 928 |  |  | $ | 2,265 |
Foreign | 3,123 |  |  | 2,435 |  |  | 1,164 |
State | (15) |  |  | 48 |  |  | 57 |
| 4,052 |  |  | 3,411 |  |  | 3,486 |
Deferred provision |  |  |  |  |
Federal | (1,475) |  |  | (1,559) |  |  | (1,510) |
Foreign | 212 |  |  | (233) |  |  | 71 |
State | 14 |  |  | (107) |  |  | (129) |
| (1,249) |  |  | (1,899) |  |  | (1,568) |
| $ | 2,803 |  |  | $ | 1,512 |  |  | $ | 1,918 |
Deferred income taxes at December 31 consisted of:
| 2024 |  | 2023
| Assets |  | Liabilities |  | Assets |  | Liabilities
Product intangibles and licenses | $ | 71 |  |  | $ | 978 |  |  | $ | — |  |  | $ | 1,308 |
R&D capitalization | 3,062 |  |  | — |  |  | 2,099 |  |  | — |
Inventory related | 84 |  |  | 413 |  |  | 86 |  |  | 370 |
Accelerated depreciation | — |  |  | 645 |  |  | — |  |  | 626 |
Undistributed foreign earnings | 275 |  |  | 371 |  |  | 76 |  |  | 118 |
Equity investments | — |  |  | 90 |  |  | — |  |  | 73 |
Pensions and other postretirement benefits | 224 |  |  | 400 |  |  | 323 |  |  | 249 |
Compensation related | 400 |  |  | — |  |  | 357 |  |  | — |
Unrecognized tax benefits | 152 |  |  | — |  |  | 147 |  |  | — |
Net operating losses and other tax credit carryforwards | 910 |  |  | — |  |  | 868 |  |  | — |
Other | 802 |  |  | 159 |  |  | 755 |  |  | 214 |
Subtotal | 5,980 |  |  | 3,056 |  |  | 4,711 |  |  | 2,958 |
Valuation allowance | (710) |  |  |  |  | (656) |  |  |
Total deferred taxes | $ | 5,270 |  |  | $ | 3,056 |  |  | $ | 4,055 |  |  | $ | 2,958 |
Net deferred income taxes | $ | 2,214 |  |  |  |  | $ | 1,097 |  |  |
Recognized as: |  |  |  |  |  |  |
Other Assets | $ | 3,601 |  |  |  |  | $ | 1,968 |  |  |
Deferred Income Taxes |  |  | $ | 1,387 |  |  |  |  | $ | 871 |
The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2024, $324 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $264 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $586 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $446 million have been established on these U.S. tax credit carryforwards and NOL carryforwards. Income taxes paid in 2024, 2023 and 2022 consisted of:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Domestic (1) | $ | 974 |  |  | $ | 2,258 |  |  | $ | 1,891 |
Foreign | 2,954 |  |  | 2,080 |  |  | 1,348 |
| $ | 3,928 |  |  | $ | 4,338 |  |  | $ | 3,239 |
(1) Includes TCJA transition tax payments. Tax benefits relating to stock option exercises were $26 million in 2024, $12 million in 2023 and $45 million in 2022. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
| 2024 |  | 2023 |  | 2022
Balance January 1 | $ | 2,384 |  |  | $ | 1,835 |  |  | $ | 1,529 |
Additions related to current year positions | 421 |  |  | 553 |  |  | 344 |
Additions related to prior year positions | 35 |  |  | 91 |  |  | 48 |
Reductions for tax positions of prior years | (33) |  |  | (20) |  |  | (40) |
Settlements | (18) |  |  | (23) |  |  | (6) |
Lapse of statute of limitations (1) | (528) |  |  | (52) |  |  | (40) |
Balance December 31 | $ | 2,261 |  |  | $ | 2,384 |  |  | $ | 1,835 |
(1) Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years. If the Company were to recognize the unrecognized tax benefits of $2.3 billion at December 31, 2024, the income tax provision would reflect a favorable net impact of $2.2 billion. The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2024 could decrease by up to approximately $22 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. Interest and penalties associated with uncertain tax positions amounted to an expense of $51 million in 2024, $131 million in 2023 and $54 million in 2022. These amounts reflect the beneficial impacts of various tax settlements. Liabilities for accrued interest and penalties were $437 million and $388 million as of December 31, 2024 and 2023, respectively. In 2024, the Company recorded a benefit of $519 million due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration in 2024 of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years. The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2009 through 2024.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration